logo

For the Inventor, By the Inventor

East Lyme, CT, United States of America

David A Clark

This inventor holds 10 USPTO granted patents. Top assignee: Pfizer Corporation. Active years: 1988-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David A Clark. Retrieved from https://idiyas.com/inventor/david-a-clark-p0o1cr0q

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 100.0

Average Co-Inventor Count = 2.3

ph-index = 8

Forward Citations = 219(Granted Patents)


Location History:

  • Groton, CT (US) (1992)
  • East Lyme, CT (US) (1988 - 2001)

Company Filing History:

goldMedal10 out of 4,488 
 
Pfizer Corporation
 patents

Years Active: 1988-2001

Loading Chart...
10 patents (USPTO):Explore Patents
1. 6329408 - Hypoglycemic thiazolidinediones and intermediates (2001-12-11),
2. 5498621 - Oxazolidinedione hypoglycemic agents (1996-03-12),
3. 5330998 - Thiazolidinedione derivatives as hypoglycemic agents (1994-07-19),
4. 5223522 - Thiazolidinedione hypoglycemic agents (1993-06-29),
5. 5130379 - Hypoglycemic thiazolidinedione derivatives (1992-07-14),
6. 5120754 - Thiazolidinedione hypoglycemic agents (1992-06-09),
7. 5061717 - Thiazolidinedione hypoglycemic agents (1991-10-29),
8. 5036079 - Hypoglycemic thiazolidinedione derivatives (1991-07-30),
9. 4968707 - Oxazolidin-2-one derivatives as hypoglycemic agents (1990-11-06),
10. 4791125 - Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents (1988-12-13),

Title: The Innovations of David A. Clark

Introduction

David A. Clark is a prominent inventor based in East Lyme, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of hypoglycemic agents. With a total of 10 patents to his name, Clark's work has had a substantial impact on medical science.

Latest Patents

Among his latest patents are innovative compounds such as hypoglycemic thiazolidinediones and intermediates, which include optically pure thiazolidinedione alcohols and ethers. These compounds are recognized for their utility as hypoglycemic and hypocholesterolemic agents. Additionally, he has developed oxazolidinedione hypoglycemic agents, which are characterized by specific chemical formulae that demonstrate their effectiveness in managing blood sugar levels.

Career Highlights

David A. Clark is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to focus on groundbreaking research and development in the field of diabetes treatment. His contributions have been instrumental in advancing therapeutic options for patients.

Collaborations

Throughout his career, Clark has collaborated with notable colleagues, including Bernard Hulin and Steven Wayne Goldstein. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

David A. Clark's contributions to the field of pharmaceuticals, particularly in the development of hypoglycemic agents, highlight his role as a significant inventor. His work continues to influence the medical community and improve patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…